ATLAS (AltaValve) Pivotal Trial
ATLAS
ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) Pivotal Trial
1 other identifier
interventional
450
7 countries
58
Brief Summary
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2024
Longer than P75 for not_applicable
58 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2024
CompletedFirst Posted
Study publicly available on registry
June 20, 2024
CompletedStudy Start
First participant enrolled
September 3, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2031
August 3, 2026
July 1, 2026
5 years
June 5, 2024
July 31, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite of all-cause mortality or heart failure hospitalization.
12 months.
Secondary Outcomes (6)
All-cause mortality, disabling stroke, acute kidney injury (stage 3 or with renal replacement), mitral valve re-intervention (surgical or transcatheter), major bleeding requiring intervention.
30 Days or hospital discharge (whichever is longer).
Technical success.
Day 0.
Mitral valve re-intervention.
At 30 days, 6 months, 1 year, and annually thereafter for up to 5 years.
Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ).
6 months and 1 year.
Changes in Six-minute walk test (6MWT).
6 months and 1 year.
- +1 more secondary outcomes
Study Arms (2)
Primary Cohort
EXPERIMENTALDesigned to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population without at least moderate mitral annular calcification (MAC).
Mitral Annular Calcification Cohort (MAC)
EXPERIMENTALDesigned to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population with moderate to severe MAC.
Interventions
Transcatheter Mitral Valve Replacement.
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years.
- Symptomatic New York Heart Association (NYHA) class II-IV.
- Moderate-to-severe or severe MR (3+) despite optimal guideline-directed medical therapy (GDMT) as determined by an independent Echo Core Lab.
- Unsuitable for surgery and Transcatheter Edge-toEdge Repair (TEER) as determined by the local site Heart Team.
You may not qualify if:
- Inability to understand the trial or a history of non-compliance with medical advice.
- Inability to provide signed Informed Consent Form (ICF).
- History of any cognitive or mental health status that would interfere with participation in the trial.
- Currently enrolled in any other pre-approval investigational trial (does not apply to long-term post-market trials unless these trials might clinically interfere with the current trial endpoints (e.g., limit use of trial-required medication, etc.)).
- Female subjects who are pregnant or planning to become pregnant within the trial period.
- Known hypersensitivity or contraindication to heparin, or warfarin without adequate alternative medications.
- Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately medicated.
- Known hypersensitivity to contrast media that cannot be adequately medicated.
- Evidence of current left ventricular ejection fraction (LVEF) ≤ 25%.
- Concurrent medical condition with a life expectancy of less than 12 months.
- Transcatheter aortic repair or replacement within 90 days prior to the baseline required tests.
- Percutaneous coronary intervention (PCI) within 30 days prior to the index procedure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (58)
Banner University Medical Center
Phoenix, Arizona, 85006, United States
Abrazo Arizona Heart Hospital
Phoenix, Arizona, 85016, United States
Dignity Health; St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85032, United States
TMC Healthcare
Tucson, Arizona, 85712, United States
Scripps Health
La Jolla, California, 92037, United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Orange County Heart Institute & Research Center
Orange, California, 92868, United States
Sutter Bay Hospitals
San Francisco, California, 94107, United States
Los Robles Hospital & Medical Center
Thousand Oaks, California, 91360, United States
Baptist Medical Center
Jacksonville, Florida, 32207, United States
NCH Healthcare System
Naples, Florida, 34102, United States
Sarasota Memorial Health Care System
Sarasota, Florida, 34239, United States
Wellstar Center for Cardiovascular Care
Atlanta, Georgia, 30060, United States
Cardiovascular Institute of the South
Houma, Louisiana, 70360, United States
MedStar Health Research Institute, Inc.
Baltimore, Maryland, 21218, United States
MedStar Health Research Institute, Inc.
Columbia, Maryland, 21044, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, 55407, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111, United States
Washington University
St Louis, Missouri, 63110, United States
AHS Hospital Corp.
Morristown, New Jersey, 07960, United States
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York, 10032, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
The Charlotte-Mecklenburg Hospital; Atrium Health
Charlotte, North Carolina, 28203, United States
East Carolina Heart Institute at East Carolina University
Greenville, North Carolina, 27834, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
South Oklahoma Heart Research, LLC.
Oklahoma City, Oklahoma, 73135, United States
Oregon Health & Science University
Portland, Oregon, 97239, United States
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
University of Virginia
Charlottesville, Virginia, 22903, United States
University of Washington
Seattle, Washington, 98195, United States
St. Paul's Hospital
Vancouver, British Colombia, V6Z 2K5, Canada
St. Michael's Unity Health Toronto
Toronto, Ontario, M5B 1W8, Canada
Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Québec, Quebec, G1V 4G5, Canada
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33404, France
L'Assistance Publique-Hôpitaux de Marseille (AP-HM)
Marseille, 13554, France
Société d'Exploitation du Centre Cardiologique du Nord
Paris, France
Clinique Pasteur
Toulouse, 31076, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitatsklinikum Bonn
Bonn, Germany
University Hospital Cologne - Heart Center
Cologne, Germany
Cardiac Research GmbH; St.-Johannes-Hospital Dortmund
Dortmund, Germany
Universitätsmedizin der Johannes Gutenberg Universität Mainz
Mainz, Germany
University Hospital of the Ruhr University Bochum
Oeynhausen, Germany
Heart Center Trier
Trier, Germany
Universitiitsklinikum Ulm
Ulm, 50937, Germany
Onassis Cardiac Surgery Center
Athens, Greece
Univeristy Hospital of Ioannina
Ioannina, Greece
Interbalkan Medical Center of Thessaloniki
Thessaloniki, Greece
Uniwersyteckim Szpitalem Klinicznym
Poznan, 60-355, Poland
Hospital Clinic de Barcelona
Barcelona, Spain
Fundación para la investigación biomédica del hospital clínico San Carlos
Madrid, Spain
Hospital Álvaro Cunqueiro
Vigo, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2024
First Posted
June 20, 2024
Study Start
September 3, 2024
Primary Completion (Estimated)
September 1, 2029
Study Completion (Estimated)
September 1, 2031
Last Updated
August 3, 2026
Record last verified: 2026-07